LPTX - Leap Therapeutics Inc Stock Price, Fair Value and News

3.28USD+0.08 (+2.50%)Market Closed

Market Summary

USD3.28+0.08

Market Closed

2.50%

LPTX Stock Price

View Fullscreen

LPTX RSI Chart

LPTX Valuation

Market Cap

81.9M

Price/Earnings (Trailing)

-1.01

Price/Sales (Trailing)

74.41

EV/EBITDA

-0.14

Price/Free Cashflow

-1.87

LPTX Price/Sales (Trailing)

LPTX Profitability

EBT Margin

-7394.55%

Return on Equity

-135.37%

Return on Assets

-111.79%

Free Cashflow Yield

-53.41%

LPTX Fundamentals

LPTX Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-15.03%

Rev. Growth (Qtr)

85.91%

LPTX Earnings

Earnings (TTM)

-81.4M

Earnings Growth (Yr)

-3%

Earnings Growth (Qtr)

8.99%

Breaking Down LPTX Revenue

Last 7 days

7.7%

Last 30 days

27.4%

Last 90 days

20.7%

Trailing 12 Months

808.8%

How does LPTX drawdown profile look like?

LPTX Financial Health

Current Ratio

5.64

LPTX Investor Care

Shares Dilution (1Y)

158.18%

Diluted EPS (TTM)

-4.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.3M	2.0M	1.9M	1.1M
2022	1.4M	1.6M	1.8M	2.1M
2021	1.8M	1.8M	2.9M	1.2M
2020	2.2M	2.5M	2.8M	1.8M
2019	1.0M	1.3M	1.6M	1.9M
2018	1.5M	1.2M	995.8K	756.0K
2017	2.8M	2.4M	2.1M	1.7M
2016	0	0	0	3.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Leap Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 26, 2024	mirabelli christopher	acquired	-	-	5,000	chairman of the board
Jan 26, 2024	lawlor augustine	acquired	-	-	5,000	chief operating officer
Jan 26, 2024	onsi douglas e	acquired	-	-	7,500	ceo,cfo,pres.,gc,treas.,&sec.
Jan 26, 2024	sirard cynthia	acquired	-	-	5,000	chief medical officer
Jan 26, 2024	o'mahony john mark	acquired	-	-	5,000	chief manufacturing officer
Mar 17, 2023	onsi douglas e	acquired	-	-	660,606	ceo,cfo,pres.,gc,treas.,&sec.
Sep 24, 2021	beigene, ltd.	bought	7,249,830	2.85	2,543,800	-
Dec 28, 2020	healthcare ventures viii, l.p.	sold	-	-	-2,618,410	-
Jun 22, 2020	perceptive advisors llc	bought	3,500,000	2.00	1,750,000	-
Feb 05, 2019	mirabelli christopher	bought	999,999	1.75	571,428	ceo, president, chairman

Which funds bought or sold LPTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	-6.00	11.00	-%
Apr 15, 2024	Key Client Fiduciary Advisors, LLC	added	8.58	-269,731	619,828	0.33%
Apr 08, 2024	TOMPKINS FINANCIAL CORP	unchanged	-	-178	319	-%
Mar 11, 2024	VANGUARD GROUP INC	added	22.43	1,236,730	1,698,640	-%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	124,345	186,404	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-30,000	-	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	reduced	-73.17	-118,000	495,000	-%
Feb 15, 2024	BARCLAYS PLC	sold off	-100	-	-	-%
Feb 14, 2024	BAKER BROS. ADVISORS LP	unchanged	-	3,241,060	4,858,660	0.06%
Feb 14, 2024	JANUS HENDERSON GROUP PLC	sold off	-100	-423,398	-	-%

Are Funds Buying or Selling LPTX?

Are funds buying LPTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LPTX

No. of Funds

Unveiling Leap Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 19, 2024	gilead sciences, inc.	13.9%	5,319,148	SC 13G
Feb 14, 2024	perceptive advisors llc	4.0%	1,068,497	SC 13G/A
Feb 14, 2023	perceptive advisors llc	6.8%	6,726,496	SC 13G/A
Feb 15, 2022	perceptive advisors llc	9.6%	8,476,496	SC 13G/A
Feb 14, 2022	hhlr advisors, ltd.	0%	0	SC 13G/A
Feb 11, 2022	artal international s.c.a.	4.5%	4e+06	SC 13G/A
Feb 10, 2022	eli lilly & co	3.5%	3,151,605	SC 13G/A
Sep 29, 2021	beigene, ltd.	13.2%	12,153,074	SC 13D/A
Feb 16, 2021	hillhouse capital advisors, ltd.	6.2%	3,716,240	SC 13G
Feb 16, 2021	perceptive advisors llc	14.2%	8,476,496	SC 13G/A

Recent SEC filings of Leap Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	3	Insider Trading
Apr 19, 2024	SC 13G	Major Ownership Report
Apr 11, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	S-3	S-3
Feb 14, 2024	SC 13G/A	Major Ownership Report
Jan 31, 2024	4	Insider Trading
Jan 31, 2024	4	Insider Trading
Jan 31, 2024	4	Insider Trading

Peers (Alternatives to Leap Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Leap Therapeutics Inc News

Latest updates

Leap Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-100.0%	-	554,000	298,000	272,000	775,000	652,000	587,000	814,333	1,041,667	1,269,000	375,000	375,000	839,500	228,000	375,000	375,000	1,794,000	927,500	61,000	75,000	187,000
Operating Expenses	-0.1%	14,820,000	14,833,000	14,662,000	42,726,000	13,943,000	15,288,000	16,900,000	10,632,000	10,863,000	12,515,000	10,001,000	9,547,000	7,529,000	7,883,000	7,871,000	6,756,000	8,272,000	7,923,000	8,461,000	8,795,000	8,971,000
S&GA Expenses	-5.9%	3,135,000	3,330,000	3,558,000	3,784,000	2,909,000	3,186,000	2,855,000	2,848,000	2,793,000	2,438,000	2,795,000	2,740,000	2,428,000	2,514,000	2,521,000	2,153,000	2,604,000	2,151,000	2,325,000	2,005,000	2,063,000
R&D Expenses	1.6%	11,685,000	11,503,000	11,104,000	38,942,000	11,034,000	12,102,000	14,045,000	7,784,000	8,070,000	10,077,000	7,206,000	6,807,000	5,101,000	5,369,000	5,350,000	4,603,000	5,668,000	5,772,000	6,136,000	6,790,000	6,908,000
EBITDA Margin	-158.2%	-73.93	-28.64	-27.23	-23.79	-26.51	-21.98	-24.74	-28.30	-33.07	-12.75	-17.80	-16.15	-15.10	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	5,000	11,000	17,000	21,000	2,000	9,000	16,000	14,000	-3,000	17,000	13,000	12,000	2,000	5,000	9,000	7,000	1,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-10,812,000	-11,139,000	-9,526,000	-9,134,000	-6,712,000	-7,057,000	-6,516,000	-7,231,000	-7,999,000	-7,935,000	-8,366,000	-8,603,000	-
EBT Margin	-157.9%	-73.95	-28.67	-27.27	-23.82	-26.55	-22.01	-24.79	-28.35	-33.12	-12.77	-17.84	-16.19	-15.14	-	-	-	-	-	-	-	-
Net Income	9.0%	-12,465,000	-13,696,000	-13,390,000	-41,863,000	-12,102,000	-15,094,000	-17,024,000	-10,376,000	-10,788,000	-11,139,000	-9,526,000	-9,134,000	-6,710,000	-7,057,000	-6,516,000	-7,231,000	-7,996,000	-7,935,000	-8,366,000	-8,603,000	1,480,000
Net Income Margin	-73.3%	-73.95	-42.68	-41.29	-37.66	-26.62	-28.88	-30.10	-29.21	-33.11	-12.77	-17.84	-16.19	-15.14	-	-	-	-	-	-	-	-
Free Cashflow	1.0%	-10,380,000	-10,488,000	-10,185,000	-12,700,000	-13,014,000	-12,253,000	-12,259,000	-11,518,000	-10,716,000	-8,102,000	-7,752,000	-8,587,000	-5,988,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.3%	73.00	83.00	96.00	107	70.00	82.00	94.00	106	118	128	38.00	46.00	54.00	61.00	68.00	29.00	7.00	14.00	20.00	26.00	19.00
Current Assets	-12.4%	72.00	82.00	94.00	105	68.00	80.00	92.00	105	117	125	36.00	44.00	52.00	58.00	65.00	26.00	4.00	11.00	17.00	23.00	17.00
Cash Equivalents	-12.5%	71.00	81.00	91.00	102	66.00	78.00	91.00	103	115	125	36.00	43.00	52.00	52.00	65.00	25.00	4.00	10.00	16.00	22.00	16.00
Net PPE	-44.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	14.9%	13.00	11.00	12.00	11.00	11.00	12.00	11.00	7.00	10.00	11.00	8.00	7.00	8.00	7.00	8.00	11.00	9.00	9.00	9.00	9.00	10.00
Current Liabilities	14.9%	13.00	11.00	12.00	10.00	11.00	12.00	10.00	7.00	10.00	11.00	8.00	7.00	7.00	7.00	7.00	9.00	8.00	8.00	8.00	8.00	6.00
Shareholder's Equity	-16.5%	60.00	72.00	84.00	28.00	59.00	70.00	83.00	99.00	108	117	30.00	38.00	47.00	53.00	60.00	18.00	-	6.00	11.00	17.00	9.00
Retained Earnings	-3.2%	-399	-387	-373	-360	-318	-306	-290	-273	-263	-252	-241	-232	-222	-216	-209	-202	-195	-187	-179	-170	-153
Additional Paid-In Capital	0.3%	460	458	457	388	377	375	374	373	372	370	272	271	270	269	269	220	193	192	190	188	162
Shares Outstanding	0%	26.00	26.00	26.00	12.00	10.00	11.00	11.00	11.00	6.00	8.00	8.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	78.00	-	-	-	94.00	-	-	-	86,766,207	-	-	-	109	-	-	-	28.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	1.0%	-10,380	-10,488	-10,185	-12,700	-13,014	-12,253	-12,259	-11,518	-10,716	-8,102	-7,752	-8,587	-5,988	-6,592	-9,451	-3,926	-5,894	-6,957	-7,183	-6,868	-7,050
Share Based Compensation	-3.6%	1,253	1,300	1,265	1,310	1,457	1,253	1,266	1,204	938	1,003	912	833	715	670	617	570	936	950	899	947	925
Cashflow From Investing	-	-	-	-348	49,317	-	-	-	-	-	-	-	-	-	-	-	-	15.00	-	-	-	-
Cashflow From Financing	100.0%	-	-1.00	-	-29.00	-	-	-	-210	755	97,262	4.00	14.00	-	-385	48,777	25,605	-19.00	1,254	1,260	12,322	-40.00

LPTX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 73,234	$ 44,965
General and administrative	13,807	11,798
Total operating expenses	87,041	56,763
Loss from operations	(87,041)	(56,763)
Interest income	4,027	925
Interest expense		(54)
Australian research and development incentives	1,101	2,051
Other income	500
Foreign currency loss	(13)	(608)
Change in fair value of Series X preferred stock warrant liability	12
Loss before income taxes	81,414	54,449
Provision for income taxes		(147)
Net loss attributable to common stockholders	$ (81,414)	$ (54,596)
Net loss per share
Basic (in dollars per share)	$ (3.98)	$ (4.82)
Diluted (in dollars per share)	$ (3.98)	$ (4.82)
Weighted average common shares outstanding
Basic (in shares)	20,445,109	11,323,909
Diluted (in shares)	20,445,109	11,323,909

LPTX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 70,643	$ 65,500
Research and development incentive receivable	771	2,099
Prepaid expenses and other current assets	183	351
Total current assets	71,597	67,950
Property and equipment, net	5	20
Right of use assets, net	257	669
Deferred costs	0	576
Other long term assets		30
Deposits	966	1,108
Total assets	72,825	70,353
Current liabilities:
Accounts payable	6,465	5,657
Accrued expenses	5,957	5,152
Lease liability - current portion	262	416
Total current liabilities	12,684	11,225
Non current liabilities:
Lease liability, net of current portion		262
Total liabilities	12,684	11,487
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.001 par value; 240,000,000 shares authorized; 25,565,414 and 9,902,137 shares issued and outstanding as of December 31, 2023 and 2022, respectively	26	10
Additional paid-in capital	459,591	376,896
Accumulated other comprehensive income	106	128
Accumulated deficit	(399,582)	(318,168)
Total stockholders' equity	60,141	58,866
Total liabilities and stockholders' equity	$ 72,825	$ 70,353

About Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

CEO	Mr. Douglas E. Onsi J.D.
WEBSITE	leaptx.com
INDUSTRY	Biotechnology
EMPLOYEES	44

Leap Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Leap Therapeutics Inc? What does LPTX stand for in stocks?

LPTX is the stock ticker symbol of Leap Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Leap Therapeutics Inc (LPTX)?

As of Tue Apr 23 2024, market cap of Leap Therapeutics Inc is 81.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LPTX stock?

You can check LPTX's fair value in chart for subscribers.

What is the fair value of LPTX stock?

You can check LPTX's fair value in chart for subscribers. The fair value of Leap Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Leap Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LPTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Leap Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LPTX is over valued or under valued. Whether Leap Therapeutics Inc is cheap or expensive depends on the assumptions which impact Leap Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LPTX.

What is Leap Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, LPTX's PE ratio (Price to Earnings) is -1.01 and Price to Sales (PS) ratio is 74.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPTX PE ratio will change depending on the future growth rate expectations of investors.